Published in Eur Heart J on October 22, 2010
JUPITER - Crestor 20mg Versus Placebo in Prevention of Cardiovascular (CV) Events | NCT00239681
Primary prevention of coronary heart disease: integration of new data, evolving views, revised goals, and role of rosuvastatin in management. A comprehensive survey. Drug Des Devel Ther (2011) 1.68
Statins as anti-inflammatory agents in atherogenesis: molecular mechanisms and lessons from the recent clinical trials. Curr Pharm Des (2012) 1.42
Estimating treatment effects for individual patients based on the results of randomised clinical trials. BMJ (2011) 1.32
Rosuvastatin: a review of the pharmacology and clinical effectiveness in cardiovascular disease. Clin Med Insights Cardiol (2012) 0.96
JUPITER and satellites: Clinical implications of the JUPITER study and its secondary analyses. World J Cardiol (2011) 0.75
A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med (1999) 82.86
MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet (2002) 44.28
Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med (2008) 43.36
Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE project. Eur Heart J (2003) 17.80
C-reactive protein concentration and risk of coronary heart disease, stroke, and mortality: an individual participant meta-analysis. Lancet (2009) 11.81
European guidelines on cardiovascular disease prevention in clinical practice. Third Joint Task Force of European and Other Societies on Cardiovascular Disease Prevention in Clinical Practice. Eur Heart J (2003) 8.51
A randomized trial of rosuvastatin in the prevention of venous thromboembolism. N Engl J Med (2009) 4.46
Rosuvastatin for primary prevention in older persons with elevated C-reactive protein and low to average low-density lipoprotein cholesterol levels: exploratory analysis of a randomized trial. Ann Intern Med (2010) 2.94
Safety of rosuvastatin: update on 16,876 rosuvastatin-treated patients in a multinational clinical trial program. Cardiology (2007) 0.96
Biological, clinical and population relevance of 95 loci for blood lipids. Nature (2010) 28.21
Association analyses of 249,796 individuals reveal 18 new loci associated with body mass index. Nat Genet (2010) 23.08
Inflammation and atherosclerosis. Circulation (2002) 20.77
Hundreds of variants clustered in genomic loci and biological pathways affect human height. Nature (2010) 20.01
Genetic variants in novel pathways influence blood pressure and cardiovascular disease risk. Nature (2011) 13.25
Vitamin E in the primary prevention of cardiovascular disease and cancer: the Women's Health Study: a randomized controlled trial. JAMA (2005) 12.09
Fasting compared with nonfasting triglycerides and risk of cardiovascular events in women. JAMA (2007) 9.68
Progress and challenges in translating the biology of atherosclerosis. Nature (2011) 9.41
Low-dose aspirin in the primary prevention of cancer: the Women's Health Study: a randomized controlled trial. JAMA (2005) 9.03
From vulnerable plaque to vulnerable patient: a call for new definitions and risk assessment strategies: Part I. Circulation (2003) 8.61
Meta-analysis identifies 13 new loci associated with waist-hip ratio and reveals sexual dimorphism in the genetic basis of fat distribution. Nat Genet (2010) 7.94
Advances in measuring the effect of individual predictors of cardiovascular risk: the role of reclassification measures. Ann Intern Med (2009) 7.62
Blood levels of long-chain n-3 fatty acids and the risk of sudden death. N Engl J Med (2002) 7.32
Population analysis of large copy number variants and hotspots of human genetic disease. Am J Hum Genet (2009) 6.79
C-reactive protein, fibrinogen, and cardiovascular disease prediction. N Engl J Med (2012) 6.39
Inflammation in atherosclerosis: from pathophysiology to practice. J Am Coll Cardiol (2009) 6.11
Effect of sleep loss on C-reactive protein, an inflammatory marker of cardiovascular risk. J Am Coll Cardiol (2004) 6.08
Cardiovascular disease risk prediction with and without knowledge of genetic variation at chromosome 9p21.3. Ann Intern Med (2009) 6.00
Sugar-sweetened beverages and genetic risk of obesity. N Engl J Med (2012) 5.98
Hemoglobin A1c predicts diabetes but not cardiovascular disease in nondiabetic women. Am J Med (2007) 5.95
C-reactive protein and the risk of developing hypertension. JAMA (2003) 5.75
The effect of including C-reactive protein in cardiovascular risk prediction models for women. Ann Intern Med (2006) 5.69
New loci associated with kidney function and chronic kidney disease. Nat Genet (2010) 5.58
Genome-wide meta-analysis identifies 56 bone mineral density loci and reveals 14 loci associated with risk of fracture. Nat Genet (2012) 5.48
Inactivating mutations in NPC1L1 and protection from coronary heart disease. N Engl J Med (2014) 4.94
Multiple loci associated with indices of renal function and chronic kidney disease. Nat Genet (2009) 4.78
Forty-three loci associated with plasma lipoprotein size, concentration, and cholesterol content in genome-wide analysis. PLoS Genet (2009) 4.71
Interleukin-6 receptor pathways in coronary heart disease: a collaborative meta-analysis of 82 studies. Lancet (2012) 4.63
Pharmacogenetic study of statin therapy and cholesterol reduction. JAMA (2004) 4.47
Association between a literature-based genetic risk score and cardiovascular events in women. JAMA (2010) 4.46
A randomized trial of rosuvastatin in the prevention of venous thromboembolism. N Engl J Med (2009) 4.46
Inflammation as a cardiovascular risk factor. Circulation (2004) 4.26
From vulnerable plaque to vulnerable patient: a call for new definitions and risk assessment strategies: Part II. Circulation (2003) 3.94
Lipoprotein particle profiles by nuclear magnetic resonance compared with standard lipids and apolipoproteins in predicting incident cardiovascular disease in women. Circulation (2009) 3.93
Anti-inflammatory effects of statins: clinical evidence and basic mechanisms. Nat Rev Drug Discov (2005) 3.92
Lipid-related markers and cardiovascular disease prediction. JAMA (2012) 3.91
Meta-analysis identifies six new susceptibility loci for atrial fibrillation. Nat Genet (2012) 3.71
Meta-analysis of genome-wide association studies in >80 000 subjects identifies multiple loci for C-reactive protein levels. Circulation (2011) 3.68
Polymorphisms of the HNF1A gene encoding hepatocyte nuclear factor-1 alpha are associated with C-reactive protein. Am J Hum Genet (2008) 3.61
Genome-wide association study identifies six new loci influencing pulse pressure and mean arterial pressure. Nat Genet (2011) 3.40
Thirty new loci for age at menarche identified by a meta-analysis of genome-wide association studies. Nat Genet (2010) 3.37
Genome-wide meta-analysis identifies 11 new loci for anthropometric traits and provides insights into genetic architecture. Nat Genet (2013) 3.25
Genetic variants at 2q24 are associated with susceptibility to type 2 diabetes. Hum Mol Genet (2010) 3.24
Blood pressure and risk of developing type 2 diabetes mellitus: the Women's Health Study. Eur Heart J (2007) 3.21
Novel loci for adiponectin levels and their influence on type 2 diabetes and metabolic traits: a multi-ethnic meta-analysis of 45,891 individuals. PLoS Genet (2012) 3.21
Physical activity and reduced risk of cardiovascular events: potential mediating mechanisms. Circulation (2007) 3.20
Genome-wide association studies identify loci associated with age at menarche and age at natural menopause. Nat Genet (2009) 3.06
Genome-wide association analyses identify 18 new loci associated with serum urate concentrations. Nat Genet (2012) 3.04
High-density lipoprotein cholesterol, size, particle number, and residual vascular risk after potent statin therapy. Circulation (2013) 3.03
Fasting compared with nonfasting lipids and apolipoproteins for predicting incident cardiovascular events. Circulation (2008) 3.03
Lipoprotein(a) concentrations, rosuvastatin therapy, and residual vascular risk: an analysis from the JUPITER Trial (Justification for the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin). Circulation (2013) 3.02
Relation between a diet with a high glycemic load and plasma concentrations of high-sensitivity C-reactive protein in middle-aged women. Am J Clin Nutr (2002) 3.00
Association of physical activity and body mass index with novel and traditional cardiovascular biomarkers in women. JAMA (2006) 2.99
The long- and short-term impact of elevated body mass index on the risk of new atrial fibrillation the WHS (women's health study). J Am Coll Cardiol (2010) 2.96
Statin therapy and risk of developing type 2 diabetes: a meta-analysis. Diabetes Care (2009) 2.96
Rosuvastatin for primary prevention in older persons with elevated C-reactive protein and low to average low-density lipoprotein cholesterol levels: exploratory analysis of a randomized trial. Ann Intern Med (2010) 2.94
Platelet expression profiling and clinical validation of myeloid-related protein-14 as a novel determinant of cardiovascular events. Circulation (2006) 2.93
Common variants associated with plasma triglycerides and risk for coronary artery disease. Nat Genet (2013) 2.92
The American Journal of Cardiology and Journal of Periodontology Editors' Consensus: periodontitis and atherosclerotic cardiovascular disease. Am J Cardiol (2009) 2.91
Dietary calcium, vitamin D, and the prevalence of metabolic syndrome in middle-aged and older U.S. women. Diabetes Care (2005) 2.89
Novel association of ABO histo-blood group antigen with soluble ICAM-1: results of a genome-wide association study of 6,578 women. PLoS Genet (2008) 2.85
Soluble intercellular adhesion molecule-1, soluble vascular adhesion molecule-1, and the development of symptomatic peripheral arterial disease in men. Circulation (2002) 2.84
Sex-stratified genome-wide association studies including 270,000 individuals show sexual dimorphism in genetic loci for anthropometric traits. PLoS Genet (2013) 2.83
Risk factors for progression of peripheral arterial disease in large and small vessels. Circulation (2006) 2.81
Interrelationships among circulating interleukin-6, C-reactive protein, and traditional cardiovascular risk factors in women. Arterioscler Thromb Vasc Biol (2002) 2.79
C-reactive protein levels are not associated with increased risk for colorectal cancer in women. Ann Intern Med (2005) 2.79
Prospective study of C-reactive protein, homocysteine, and plasma lipid levels as predictors of sudden cardiac death. Circulation (2002) 2.78
FTO genotype is associated with phenotypic variability of body mass index. Nature (2012) 2.77
Multiple genetic loci influence serum urate levels and their relationship with gout and cardiovascular disease risk factors. Circ Cardiovasc Genet (2010) 2.76
C-reactive protein and other inflammatory risk markers in acute coronary syndromes. J Am Coll Cardiol (2003) 2.51
Serum amyloid A as a predictor of coronary artery disease and cardiovascular outcome in women: the National Heart, Lung, and Blood Institute-Sponsored Women's Ischemia Syndrome Evaluation (WISE). Circulation (2004) 2.50
On the use of variance per genotype as a tool to identify quantitative trait interaction effects: a report from the Women's Genome Health Study. PLoS Genet (2010) 2.48
A statin-dependent QTL for GATM expression is associated with statin-induced myopathy. Nature (2013) 2.46
A meta-analysis of genome-wide association studies of breast cancer identifies two novel susceptibility loci at 6q14 and 20q11. Hum Mol Genet (2012) 2.45
Cardiovascular risk prediction in diabetic men and women using hemoglobin A1c vs diabetes as a high-risk equivalent. Arch Intern Med (2011) 2.43
Genome-wide association of lipid-lowering response to statins in combined study populations. PLoS One (2010) 2.43
Inflammation and atherosclerosis: role of C-reactive protein in risk assessment. Am J Med (2004) 2.39
Low-density lipoprotein particle concentration and size as determined by nuclear magnetic resonance spectroscopy as predictors of cardiovascular disease in women. Circulation (2002) 2.36
Tree and spline based association analysis of gene-gene interaction models for ischemic stroke. Stat Med (2004) 2.35
Aspirin triggers antiinflammatory 15-epi-lipoxin A4 and inhibits thromboxane in a randomized human trial. Proc Natl Acad Sci U S A (2004) 2.34
Comparison of LDL cholesterol concentrations by Friedewald calculation and direct measurement in relation to cardiovascular events in 27,331 women. Clin Chem (2009) 2.31
Genetic determinants of statin-induced low-density lipoprotein cholesterol reduction: the Justification for the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER) trial. Circ Cardiovasc Genet (2012) 2.26
C-reactive protein in the prediction of rheumatoid arthritis in women. Arch Intern Med (2006) 2.22
Systematic review and meta-analysis of methotrexate use and risk of cardiovascular disease. Am J Cardiol (2011) 2.20
The American Journal of Cardiology and Journal of Periodontology editors' consensus: periodontitis and atherosclerotic cardiovascular disease. J Periodontol (2009) 2.20
Circulating levels of endothelial adhesion molecules and risk of diabetes in an ethnically diverse cohort of women. Diabetes (2007) 2.19
Comparison of the Framingham and Reynolds Risk scores for global cardiovascular risk prediction in the multiethnic Women's Health Initiative. Circulation (2012) 2.17
Elevated C-reactive protein levels are associated with postoperative events in patients undergoing lower extremity vein bypass surgery. J Vasc Surg (2006) 2.14
Meta-analyses identify 13 loci associated with age at menopause and highlight DNA repair and immune pathways. Nat Genet (2012) 2.12
C-reactive protein levels among women of various ethnic groups living in the United States (from the Women's Health Study). Am J Cardiol (2004) 2.08
Fried food consumption, genetic risk, and body mass index: gene-diet interaction analysis in three US cohort studies. BMJ (2014) 2.06
Homocysteine, 5,10-methylenetetrahydrofolate reductase 677C>T polymorphism, nutrient intake, and incident cardiovascular disease in 24,968 initially healthy women. Clin Chem (2007) 2.05
Effect of intensive glycemic control on levels of markers of inflammation in type 1 diabetes mellitus in the diabetes control and complications trial. Circulation (2005) 2.02
Lipoprotein(a) and risk of type 2 diabetes. Clin Chem (2010) 2.01
Biomarkers of inflammation and thrombosis as predictors of near-term mortality in patients with peripheral arterial disease: a cohort study. Ann Intern Med (2008) 2.01
Genome-wide association study reveals three susceptibility loci for common migraine in the general population. Nat Genet (2011) 1.98